Followers | 221 |
Posts | 14753 |
Boards Moderated | 2 |
Alias Born | 03/17/2009 |
Tuesday, August 23, 2011 4:52:22 PM
NuPathe Migraine Patch Faces Decision Day
By Brett Chase Aug 19, 2011 1:15 pm
The patch was shown to be effective and safe in company studies. Investors bailed following a sale of stock to one investor.
At the end of the month, the small specialty drug company NuPathe (PATH) will learn whether its patch for migraine headaches can be sold in the US. A number of investors are choosing not to hang around and find out.
NuPathe is down more than 50% this year as it inches closer to the August 29 deadline for the Food and Drug Administration to make it decision on Zelrix, a transdermal patch that delivers an older medicine, sumatriptan. The patch uses an electrical current to make sure the medicine is delivered through the skin.
Why do we need a patch to deliver a medicine that’s already on the market? NuPathe says some migraine sufferers delay taking sumatriptan pills when they’re vomiting or even nauseous (common conditions with migraines). NuPathe say these people may be more prone to wear the patch over taking a pill. The company also says the delivery of the medicine may be more consistent using a patch. Citing its own research, the company says the patch may have fewer side effects as existing products, including chest tightening, tingling and numbness of extremities.
The drug was tested against a placebo in company studies and found to be effective and generally safe. As part of its third and last phase of studies NuPathe conducted for approval consideration, the company tested to make sure the patch didn’t cause skin irritation. In a regulatory filing, the company says it may be asked by the FDA to conduct a skin sensitivity study.
The question on approval of Zelrix comes down to the same issues as any other drug application. The FDA weighs the unmet need, the effectiveness and the safety. This isn’t another breakthrough skin cancer treatment. Migraine patients have options for treatment already. The issue of skin irritation or sensitivity already has been raised for this drug. So investors will want to weigh the risk-reward factors that FDA officials are considering here.
In recent weeks, concerns over approval have not been the main catalyst for the sell-off. Investors didn’t like the company’s agreement announced August 2 to sell up to $30 million in stock to one investor, Aspire Capital Fund, over the next two years at an agreed-upon price of $7.07 a share. The deal is seen as dilutive to the stock even though Aspire agreed to buy at a premium to the current share price.
Shares of NuPathe rose 2% to $4.42 in midday trading Friday. The stock is down almost 40% in the past month.
For those investors who believe the company’s drug has a good shot at winning approval, some analysts predict stock will more than triple in the next year.
Leerink Swann analyst Joseph Schwartz is one such bull. He puts Zelrix approval at 90% probability and recommends buying the stock with a 12-month price target of $17 a share.
While it’s potentially a big drug for a small company, bear in mind Zelrix isn’t being touted by anyone as a future blockbuster.
Sales in five years may exceed $200 million, Stifel Nicolaus analyst Annabel Samimy estimates. She recommends buying the stock with a price target of $13 a share.
“We remain optimistic on the Zelrix opportunity and expect it to quickly find its place in the market,” she says in a recent note
My post are for entertainment only...if you knew me better I'd be on ignore
Recent PATH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:05:25 PM
- UiPath Kicks Off Annual AI25 Awards to Recognize the Most Innovative Uses of AI and Business Automation • Business Wire • 05/14/2024 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/09/2024 09:06:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/09/2024 09:00:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 11:48:39 PM
- UiPath Announces First Quarter Fiscal 2025 Financial Results Conference Call • Business Wire • 05/08/2024 08:10:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/06/2024 08:22:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/06/2024 08:21:43 PM
- UiPath Named a Leader in the 2024 Gartner® Magic Quadrant™ for Process Mining • Business Wire • 05/02/2024 03:00:00 PM
- UiPath Announces Raghu Malpani Joins Company as Chief Technology Officer • Business Wire • 05/01/2024 12:00:00 PM
- UiPath Named a Leader for Second Consecutive Year in the Everest Group Intelligent Document Processing (IDP) Products PEAK Matrix® Assessment 2024 • Business Wire • 04/08/2024 12:00:00 PM
- UiPath Announces Sebastian Schrötel Joins Product Leadership Team to Lead UiPath Autopilot™ and Developer Experiences • Business Wire • 04/01/2024 12:00:00 PM
- UiPath Announces FedRAMP® Authorization for Its Automation Cloud™ Public Sector • Business Wire • 03/26/2024 12:00:00 PM
- UiPath Unveils New Family of LLMs at AI Summit to Empower Enterprises to Harness Full Capabilities of GenAI • Business Wire • 03/19/2024 12:00:00 PM
- Fisker’s Shares Take a Hit Amid Speculation of Bankruptcy, Altria Divests from AB InBev to Fund Stock Repurchase Initiative • IH Market News • 03/14/2024 11:39:32 AM
- UiPath Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results • Business Wire • 03/13/2024 08:10:00 PM
- Mixed Futures Amidst Quiet Economic Schedule; Oil Prices Climb • IH Market News • 03/13/2024 11:03:39 AM
- Saudi Arabia Ministry of Tourism Boosts Vision for Excellence and Sustainable Growth with UiPath AI and Automation • Business Wire • 03/06/2024 01:05:00 PM
- UiPath Announces Investments in Saudi Arabia, Including First Saudi School of Automation and New Office Location in Riyadh • Business Wire • 03/04/2024 08:00:00 AM
- UiPath and Google Cloud Expand Strategic Partnership to Accelerate Access to Gen AI and Cloud-based Automation • Business Wire • 02/29/2024 01:00:00 PM
- UiPath to Exhibit AI-powered Automation Solutions for Healthcare Industry at ViVE 2024 Conference • Business Wire • 02/22/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 01:03:36 AM
- UiPath Announces New Developer Features at DevCon 2024 to Bring Latest in AI-powered Productivity to Developer Community • Business Wire • 02/16/2024 03:30:00 AM
- UiPath and Deloitte Collaborate to Introduce Turnkey Automation Offering for Growth Companies • PR Newswire (US) • 02/15/2024 09:30:00 PM
- UiPath Announces Fourth Quarter and Full Year Fiscal 2024 Financial Results Conference Call • Business Wire • 02/14/2024 09:10:00 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM